Xenon Pharmaceuticals Inc. (XENE) Discusses Positive Top Line Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures Transcript

Core Insights - The conference call is focused on the Phase III X-TOLE2 study top line results from Xenon Pharmaceuticals [1] Group 1 - The call is being led by Kelvin, the conference operator, who introduces Colleen Alabiso, Senior Vice President of Corporate Affairs [1]